Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,257 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Product I Clear all
Terminated Phase 1Phase 2 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

NCT04108858
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma
Interventions
Copanlisib, Pertuzumab, Trastuzumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 2, 2026, 11:48 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

NCT03321643
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Richter Syndrome, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Rituximab
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 2, 2026, 11:48 AM EDT
Recruiting Phase 1 Interventional

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

NCT04697576
View directory record Official record
Conditions
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Interventions
Ipilimumab, Nivolumab, Pembrolizumab, Quadrivalent Inactivated Influenza Vaccine, Resection, Nivolumab + Relatlimab
Biological · Procedure
Lead sponsor
Carlo Contreras
Other
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 2, 2026, 11:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

NCT03233724
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal, Malignant Pleural Mesotheliomas
Interventions
Decitabine (DAC), Tetrahydrouridine (THU), Pembrolizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 2, 2026, 11:48 AM EDT
Not yet recruiting Phase 2 Interventional

THC Versus THC/CBD Versus Placebo to Improve Sleep Quality for Patients With Solid Organ Cancer and Insomnia

NCT07565974
View directory record Official record
Conditions
Insomnia, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Placebo Administration, Single Agent Therapy
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 2, 2026, 11:48 AM EDT
Withdrawn Phase 1Phase 2 Interventional

CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.

NCT04109690
View directory record Official record
Conditions
MDS
Interventions
CPX-351
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 78 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 1 Interventional

CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

NCT00323323
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
CHOP, Alemtuzumab, Plasma Samples
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 2, 2026, 11:48 AM EDT
Terminated Phase 2 Interventional Results available

Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

NCT02824913
View directory record Official record
Conditions
Dry Eye Disease
Interventions
P-321 Ophthalmic Solution, P-321 Ophthalmic Solution placebo
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 2, 2026, 11:48 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
AZD0516, AZD9574
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Fayetteville, Arkansas • Los Angeles, California • Towson, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

N-acetylcysteine and NMDA Antagonist Interactions

NCT00611897
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
N-acetylcysteine and ketamine, placebo and ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 2, 2026, 11:48 AM EDT
Active, not recruiting Not applicable Interventional

The Study in Outpatient Medicine Using Nudges to Improve Sleep

NCT06640023
View directory record Official record
Conditions
Inappropriate Prescribing
Interventions
Z-drug Default Quantity, Redirection + Accountable Justification
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 1 Interventional

Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody

NCT00538668
View directory record Official record
Conditions
Prostate Cancer
Interventions
117Lu-J591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 85 Years · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 1Phase 2 Interventional

Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies

NCT01947140
View directory record Official record
Conditions
Lymphoid Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Interventions
Pralatrexate, Romidepsin
Drug
Lead sponsor
Jennifer Amengual
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Sep 2, 2026, 11:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma

NCT01189240
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab, laboratory biomarker analysis, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 2, 2026, 11:48 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

NCT02166463
View directory record Official record
Conditions
Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Childhood Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Interventions
Bleomycin Sulfate, Brentuximab Vedotin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Methylprednisolone, Pharmacological Study, Prednisone, Quality-of-Life Assessment, Questionnaire Administration, Vincristine Sulfate
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 22 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
182
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 140 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients

NCT00001074
View directory record Official record
Conditions
HIV Infections
Interventions
Hydroxyurea, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
18
States / cities
San Diego, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS

NCT00000971
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clarithromycin, Zidovudine, Didanosine
Drug
Lead sponsor
Abbott
Industry
Eligibility
3 Months to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2008 · Synced Sep 2, 2026, 11:48 AM EDT
Withdrawn Phase 1 Interventional

A Study of PTS for Patients With Solid Tumors

NCT03448211
View directory record Official record
Conditions
Solid Tumor
Interventions
Para-toluenesulfonamide Injection (PTS)
Drug
Lead sponsor
PTS International Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 2, 2026, 11:48 AM EDT
Recruiting Phase 1Phase 2 Interventional

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

NCT06780111
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Sacituzumab tirumotecan, Rescue Medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL

NCT01241734
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Revlimid
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Hackensack, New Jersey • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 1 Interventional

Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration

NCT01033721
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Palomid 529
Drug
Lead sponsor
Paloma Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2012 · Synced Sep 2, 2026, 11:48 AM EDT
Recruiting Not applicable Interventional

CBT Augmentation to Promote Medication Discontinuation in Pediatric OCD

NCT05609916
View directory record Official record
Conditions
Cognitive Behavioral Therapy, Obsessive-Compulsive Disorder, Obsessive-Compulsive Disorder in Children, Obsessive-Compulsive Disorder in Adolescence
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
7 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers

NCT06879067
View directory record Official record
Conditions
Safety, Tolerability
Interventions
Placebo, Foralumab Nasal
Drug
Lead sponsor
Tiziana Life Sciences LTD
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 2, 2026, 11:48 AM EDT
Not listed Not applicable Interventional

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

NCT00436709
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, adjuvant therapy, immunoscintigraphy
Biological · Drug · Other + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 2, 2026, 11:48 AM EDT